

## Dietary-challenged mice with Alzheimer-like pathology show increased energy expenditure and reduced adipocyte hypertrophy and steatosis

Stefanie Schreyer<sup>1</sup>, Nikolaus Berndt<sup>2</sup>, Johannes Eckstein<sup>3</sup>, Michael Mülleder<sup>4</sup>, Shabnam Hemmati-Sadeghi<sup>1</sup>, Charlotte Klein<sup>1</sup>, Basim Abuelnor<sup>1</sup>, Alina Panzel<sup>1</sup>, David Meierhofer<sup>5</sup>, Joachim Spranger<sup>6,7</sup>, Barbara Steiner<sup>1,\*</sup>, Sebastian Brachs<sup>6,7,\*</sup>

<sup>1</sup>Department of Neurology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin 10117, Germany

<sup>2</sup>Institute for Imaging Science and Computational Modelling in Cardiovascular Medicine, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin 13353, Germany

<sup>3</sup>Institute of Biochemistry, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin 10117, Germany

<sup>4</sup>Core Facility High Throughput Mass Spectrometry, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin 10117, Germany

<sup>5</sup>Max Planck Institute for Molecular Genetics, Berlin 14195, Germany

<sup>6</sup>Department of Endocrinology and Metabolism, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin 10117, Germany

<sup>7</sup>DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany

\*Equal contribution

**Correspondence to:** Sebastian Brachs; email: [sebastian.brachs@charite.de](mailto:sebastian.brachs@charite.de)

**Keywords:** Alzheimer's disease, diet-induced obesity, hypertrophy, energy expenditure, steatosis

**Received:** February 17, 2021

**Accepted:** March 27, 2021

**Published:** April 16, 2021

**Copyright:** © 2021 Schreyer et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### ABSTRACT

Alzheimer's disease (AD) is frequently accompanied by progressing weight loss, correlating with mortality. Counter-intuitively, weight loss in old age might predict AD onset but obesity in midlife increases AD risk. Furthermore, AD is associated with diabetes-like alterations in glucose metabolism. Here, we investigated metabolic features of amyloid precursor protein overexpressing APP23 female mice modeling AD upon long-term challenge with high-sucrose (HSD) or high-fat diet (HFD). Compared to wild type littermates (WT), APP23 females were less prone to mild HSD-induced and considerable HFD-induced glucose tolerance deterioration, despite unaltered glucose tolerance during normal-control diet. Indirect calorimetry revealed increased energy expenditure and hyperactivity in APP23 females. Dietary interventions, especially HFD, had weaker effects on lean and fat mass gain, steatosis and adipocyte hypertrophy of APP23 than WT mice, as shown by <sup>1</sup>H-magnetic-resonance-spectroscopy, histological and biochemical analyses. Proteome analysis revealed differentially regulated expression of mitochondrial proteins in APP23 livers and brains. In conclusion, hyperactivity, increased metabolic rate, and global mitochondrial dysfunction potentially add up to the development of AD-related body weight changes in APP23 females, becoming especially evident during diet-induced metabolic challenge. These findings emphasize the importance of translating this metabolic phenotyping into human research to decode the metabolic component in AD pathogenesis.

## INTRODUCTION

To date, Alzheimer's disease (AD) cannot be cured and its underlying mechanisms remain elusive [1]. Early diagnosis of AD – a crucial requirement for the application of existing symptomatic treatment – is complicated due to its multifaceted pathology and a variety of accessory symptoms, which are partially not well understood [2]. Thus, basic research focusing on these symptoms might provide important insights into pathological mechanisms leading to new approaches for diagnosis and therapy.

Worldwide, about 50 million patients suffer from AD, the most common neurodegenerative disease [3]. Brains affected by AD are characterized by extracellular amyloid-beta ( $A\beta$ ) aggregates, intracellular neurofibrillary tangles of hyperphosphorylated tau, and progressive neurodegeneration [4, 5]. Synapse and neuronal loss ultimately result in dementia [6]. For decades, AD research focused on  $A\beta$  – cleaved from the amyloid precursor protein (APP) – and its aggregation into plaques as disease etiology [7]. Nevertheless, decreasing  $A\beta$  burden using antibodies has failed to significantly improve patients' condition [8]. Thus, alternative causes came into the spotlight: Epidemiologic studies identified metabolic dysfunctions such as insulin resistance and glucose insensitivity as risk factors, potentially involved in AD pathology [9, 10]. These shared features lead to the suggestion that AD might represent brain-specific diabetes [11]. However, the exact mechanisms linking both pathologies remain unknown.

Counter-intuitively, both obesity in midlife and low body weight in old age increase the risk of developing AD [12, 13]. However, at least 30-40% of patients suffer from AD-related involuntary weight loss, aggravating as AD progresses leading to poorer health, reduced quality of life, and increased mortality [14]. Since weight loss already occurs years before the onset of clinical AD symptoms, body weight changes in old age might represent early AD manifestations potentially contributing to early diagnosis [15, 16].

Weight loss occurs with negative energy balance, i.e. lower energy intake than energy expenditure [17]. Reasons for negative energy balance might be reduced energy intake, e.g. due to reduced food intake or malabsorption [18], hypermetabolism originating from elevated resting energy expenditure, e.g. increased thermogenesis, or elevated total energy expenditure, e.g. increased physical activity [18]. Previous body weight analyses in AD patients remained inconclusive, requiring further research to elucidate underlying mechanisms of AD-related weight loss.

Here, we investigate early AD-related metabolism and body weight changes challenging the APP-overexpressing APP23 mouse model [19] with different diets before  $A\beta$ -plaque development to extensively characterize its metabolic features and the impact of different fuel sources. Thereby, we aim to gain insights into underlying mechanisms of AD-related metabolic and body weight changes, which might provide valuable information for early diagnosis or therapeutic approaches.

## RESULTS

### APP23 mice showed lower body weight due to lower fat and lean mass

To investigate the impact of APP overexpression on metabolism, APP23 and WT mice were challenged with normal-control (NCD), high-sucrose (HSD) or high-fat diet (HFD) for 20 weeks (Figure 1A, 1B). Across the experiment, all groups significantly gained body weight ( $F(4.04,52.55)=484.37$ ,  $p<0.001$ ; Figure 2A). However, APP23 mice showed a significantly lower body weight ( $F(1.00,52.55)=30.25$ ,  $p<0.001$ ). The effect of diet ( $F(1.90,52.55)=63.47$ ,  $p<0.001$ ) was most prominent in HFD (up to 41% higher body weight compared to NCD/HSD), while HSD had virtually no effect. At baseline, body weight of APP23 mice was 8% lower compared to WT mice ( $p=0.001$ ; Figure 2B). This body weight difference remained constant until week 20 in NCD- and HSD-fed mice (NCD: 6%, n.s.; HSD: 7%, n.s.; Figure 2C). After 20 weeks of dietary intervention, HFD elevated body weight up to 85% in WT mice and up to 68% in APP23 mice (both  $p<0.001$ ), while HSD had no effect on body weight. The body weight difference between genotypes rose to 15% in HFD-fed mice ( $p=0.008$ ).

Lean mass was 10% lower in APP23 mice at baseline (week 0,  $p<0.001$ ; Figure 2D). After 20 weeks of dietary intervention, lean mass was up to 7% lower in NCD- and HSD-fed APP23 mice, however not significant, and 8% lower in HFD-fed APP23 mice ( $p=0.087$ ; Figure 2E). While HSD did not affect lean mass, HFD significantly increased lean mass in both genotypes but more prominently in WT mice (HFD WT vs. NCD/HSD WT, both  $p<0.001$ ; HFD APP23 vs. NCD/HSD APP23, both  $p\leq 0.005$ ). Fat mass was equal between genotypes at baseline (week 0; Figure 2F). While 20 weeks of HSD had almost no effect on fat mass, HFD significantly elevated fat mass in both genotypes ( $p<0.001$ ; Figure 2G). Fat mass was 37% lower in HFD-fed APP23 mice ( $p=0.007$ ) and up to 10% lower during NCD and HSD, however not significant. Lower body weight did not originate from a smaller growth as body length was almost identical in

young adult APP23 and WT mice (Figure 2H). Notably, food intake gradually increased in WT mice from NCD to HSD to HFD (NCD WT vs. HFD WT,  $p < 0.001$ ), whereas it remained constant between diets in APP23 mice resulting in a significantly lower HFD intake compared to WT mice ( $p < 0.001$ ; Figure 2I).

In summary, APP23 mice showed lower body weight due to both lower fat and lean mass. The difference in lean mass was already present at baseline, whereas the difference in fat mass occurred only at the end of dietary intervention. APP23 mice could not catch up for this body weight difference due to a similar body weight gain.

### Diet-induced adipocyte hypertrophy and steatosis were extenuated in APP23 mice

To further examine body composition changes, tissues were analyzed upon sacrifice. Epigonadal white adipose tissue (eWAT) weight was similar between genotypes and only elevated by HFD (5-fold, vs. NCD/HSD each  $p < 0.001$ ; Figure 3A). Liver weight was also similar during NCD and elevated by HFD (e.g. NCD APP23 vs. HFD APP23,  $p < 0.001$ ) but 45% ( $p = 0.002$ ) and 20% (n.s.) lower in HSD- and HFD-fed APP23 mice (Figure 3B). Adipocyte size was analyzed in hematoxylin/eosin-stained eWAT (Figure 3C, 3D). APP23 mice displayed

20% (NCD, n.s.) to 40% (HSD, n.s.; HFD,  $p = 0.015$ ) smaller adipocytes than WT mice. In contrast to unaffected eWAT weight, HSD increased adipocyte size 2.3-fold (n.s.). HFD rose adipocyte size compared to NCD (7.3-fold, NCD WT/APP23 vs. HFD WT/APP23, both  $p < 0.001$ ) and HSD (3.1-fold, HSD WT vs. HFD WT,  $p < 0.001$ ; HSD APP23 vs. HFD APP23,  $p = 0.010$ ). Moreover, hepatic fat content (i.e. liver steatosis) was analyzed by Oil Red O staining and triglyceride quantification (Figure 3E–3G). During NCD, lipid droplet size and amount was similar, while HSD- and HFD-fed APP23 mice embodied less and smaller droplets than WT mice (HSD: 4.5-fold,  $p = 0.009$ ; HFD: 2-fold,  $p < 0.001$ ; Figure 3E, 3F). According to increasing liver weight, lipid droplet size and amount gradually rose from NCD to HFD, specifically prominent in WT mice (NCD vs. HSD: 11-fold,  $p = 0.002$ ; HSD vs. HFD: 2-fold,  $p < 0.001$ ). Furthermore, hepatic triglycerides were similar between genotypes and diets during NCD and HSD (Figure 3G). In contrast, HFD-fed WT mice showed up to 9.2-fold elevated hepatic triglycerides compared to NCD- and HSD-fed mice of both genotypes ( $p < 0.001$ ), whereas triglycerides in HFD-fed APP23 mice were only increased by 3.4-fold (n.s.). Thus, during HFD hepatic triglycerides were 2.3-fold higher in WT mice compared to APP23 mice ( $p < 0.001$ ).

**A**


Weeks	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
Procedures	BW NMR LM BL	BW	BW	BW	BW NMR BL	BW	BW	BW	BW NMR BL	BW	BW	BW	BW NMR LM BL GTT	BW	BW	BW	BW NMR BL	BW	BW	BW	BW NMR LM BL GTT

*Diet Start* (indicated between weeks 0 and 1)


**B**

Genotype	n	Diet	Total Energy [kcal/g]	Carbohydrates [% kcal] (% Sucrose % Corn starch)	Fat [% kcal]	Protein [% kcal]
WT	15	NCD	4.2	60 (2 80)	23	17
APP23	9					
WT	10	HSD	4.3	60 (96 0)	23	17
APP23	14					
WT	10	HFD	5.2	20 (34 0)	60	20
APP23	10					

**Figure 1. Experimental design and nutritional values of diets.** (A) Experimental procedures: In week 0, baseline measurements of body composition (NMR) and indirect calorimetry (LM) were conducted, as well as the first blood withdrawal (BL). Diets were fed from week 1 to 20. Body weight was assessed weekly. Monthly, NMR and BL were performed. In week 12 and 20, mice additionally underwent LM measurements and glucose tolerance tests (GTT). (B) Group layout and diet composition: 4–6-week old transgenic APP23 and WT mice were assigned to either normal-control diet (NCD), high-sucrose diet (HSD) or high-fat diet (HFD). Shown n numbers represent animal numbers for all measurements in living animals and in the animals' blood.



**Figure 2. Body weight, body composition, body length, and food intake.** (A) Development of body weight during 20 weeks of dietary intervention (NCD, HSD or HFD). (B) Body weight at baseline (week 0). (C) Body weight after 20 weeks of dietary intervention. (D) Lean mass at baseline (week 0). (E) Lean mass after 20 weeks of dietary intervention. (F) Fat mass at baseline (week 0). (G) Fat mass after 20 weeks of dietary intervention. (H) Exemplarily measured body length in male and female adult (mean age 10 weeks) APP23 and WT mice. (I) Mean daily food intake averaged over the entire intervention and across mice occupying the same cage. Data are represented as box (25<sup>th</sup> to 75<sup>th</sup> percentile) with median and whiskers from minimum to maximum. Black asterisks indicate significant differences between groups (\*:  $p < 0.05$ ; \*\*:  $p < 0.01$ ; \*\*\*:  $p < 0.001$ ), gray asterisk indicates a statistical trend towards significance ( $p < 0.1$ ) according to nonparametric ANOVA-type statistics (A), ordinary 2-way ANOVA with Tukey post-hoc test (C, G, I), multiple contrast Tukey-type test (E), or nonparametric t-test (B, D, F, H).  $n_{\text{Week 0 WT}}=35$ ,  $n_{\text{Week 0 APP23}}=31$ ,  $n_{\text{NCD WT}}=15$ ,  $n_{\text{NCD APP23}}=9$ ,  $n_{\text{HSD WT}}=10$ ,  $n_{\text{HSD APP23}}=14$ ,  $n_{\text{HFD WT}}=10$ ,  $n_{\text{HFD APP23}}=10$ ; for body length:  $n_{\text{WT}}=8$ ,  $n_{\text{APP23}}=11$ .



**Figure 3. Weight of eWAT and liver, histological analysis of adipocyte size in eWAT and lipid droplets in liver tissue, and quantification of hepatic triglycerides.** Weight of eWAT (A) and liver (B) upon sacrifice of mice after 20 weeks of dietary interventions (NCD, HSD or HFD). (C) Quantification of mean adipocyte size in eWAT sections analyzed with ImageJ (D) Representative hematoxylin/eosin stainings of eWAT tissue. Scale bar: 100  $\mu\text{m}$  (E) Lipid quantification of Oil Red O-stained hepatic sections analyzed with ImageJ. (F) Representative Oil Red O stainings of liver tissue. Arrowheads point to individual Oil Red O-stained lipid droplets. Scale bar: 100  $\mu\text{m}$ . (G) Quantification of hepatic triglycerides. Measured triglyceride concentrations were multiplied by liver weight to obtain absolute amounts of triglycerides. Data are represented as box (25<sup>th</sup> to 75<sup>th</sup> percentile) with median and whiskers from minimum to maximum. Black asterisks indicate significant differences between groups (\*:  $p < 0.05$ ; \*\*:  $p < 0.01$ ; \*\*\*:  $p < 0.001$ ), gray asterisk indicates a statistical trend towards significance ( $p < 0.1$ ) according to nonparametric multiple contrast Tukey-type test (A, B) and Tukey post-hoc test of an ordinary 2-way ANOVA (C, E, G). For (A, B)  $n_{\text{NCD WT}}=15$ ,  $n_{\text{NCD APP23}}=9$ ,  $n_{\text{HSD WT}}=10$ ,  $n_{\text{HSD APP23}}=14$ ,  $n_{\text{HFD WT}}=10$ ,  $n_{\text{HFD APP23}}=10$ . For (C, D)  $n=6$  each. For (E, F)  $n=8$  each, For (G)  $n=6$  each.



Altogether, APP23 mice resisted against HSD- and HFD-induced hepatic weight gain, lipid accumulation and adipocyte hypertrophy.

### **Insulin levels were unaltered in APP23 mice during NCD and HSD but lower during HFD**

To investigate glucose homeostasis, we monthly analyzed plasma insulin levels in fed mice (Figure 4). NCD and HSD did not alter insulin levels, with APP23 mice showing no differences compared to WT mice (Figure 4A, 4B). In contrast, HFD elevated insulin levels over time ( $F(2.75,49.50)=15.72$ ,  $p<0.001$ ), starting around week 8 of dietary intervention (Figure 4C). Interestingly, genotypes were differentially affected by the HFD-induced elevation of insulin levels ( $F(1,8)=6.915$ ,  $p=0.017$ ). In week 16 ( $p=0.019$ ) and 20 (n.s.,  $p=0.182$ ), insulin levels of WT mice were almost twice as high as those of APP23 mice. In all, only HFD elevated insulin levels, whereas APP23 mice were less affected. Additionally, corticosterone and non-esterified free fatty acid (NEFA) levels were measured in final plasma. Corticosterone levels were similar between genotypes and increased by trend from NCD to HFD (NCD WT vs. HFD WT,  $p=0.098$ ) (Figure 4D). In contrast, NEFA levels slightly decreased during HFD but similarly between genotypes (NCD APP23 vs. HFD APP23,  $p=0.062$ ; HSD APP23 vs. HFD APP23,  $p=0.023$ ; Figure 4E).

### **HFD deteriorated glucose tolerance earlier and stronger than HSD but less in APP23 mice**


To further analyze glucose homeostasis upon glucose challenge, an ipGTT was performed after 12 and 20 weeks (Figure 5, statistics see Supplementary Table 2). After 12 weeks, glucose handling was affected by diet ( $F(1.941,49.542)=50.159$ ,  $p<0.001$ ), such as HSD and HFD both delayed the glucose peak (Figure 5A). Additionally, the glucose peak of HFD-fed mice was 30% higher compared to NCD/HSD. Whereas NCD- and HSD-fed mice approximately returned to basal levels after 120 min, glucose levels remained 31% (APP23) and 82% (WT) elevated in HFD-fed mice. APP23 mice showed by trend 9% lower glucose levels than WT mice ( $F(1.000,49.541)=3.764$ ,  $p=0.052$ ). This was especially prominent in HFD-fed APP23 mice, which returned to 32% lower final glucose levels than WT mice. After 20 weeks, diet still affected glucose handling ( $F(1.943,41.614)=82.409$ ,  $p<0.001$ ) with HSD and HFD delaying the glucose peak, the effect of HFD having even grown (Figure 5B). Furthermore, HFD-fed mice remained far above basal glucose levels after 120 min (WT: 2.7-fold; APP23: 1.8-fold). Still, NCD- and HSD-fed mice nearly returned to fasting glucose levels. Again, APP23 mice showed 9% lower glucose levels

compared to WT mice ( $F(1.000,41.614)=4.183$ ,  $p=0.041$ ), which was once more especially evident in HFD-fed APP23 mice. Evaluating the area under the curve (AUC) in week 12, HFD-fed mice displayed a significantly larger AUC compared to NCD- and HSD-fed mice (Figure 5C). However, AUC of HFD-fed APP23 mice was 20% smaller compared to HFD-fed WT mice. After 20 weeks, AUC of HFD-fed mice was even more increased compared to NCD- and HSD-fed mice (Figure 5D). Still, HFD-fed APP23 mice displayed a significantly smaller AUC than HFD-fed WT mice, although the difference decreased to 15%.


Fasting glucose levels gradually increased from NCD to HSD to HFD at both time-points (Figure 5E, 5F). HSD elevated fasting glucose levels up to 25% in APP23 but not in WT mice, while HFD increased fasting glucose levels up to 35% in both genotypes. Contrary, fasting insulin levels were only increased in HFD-fed mice (week 12: 3-fold; week 20: 6-fold) in both genotypes (Figure 5G, 5H). Fasting insulin was similar between genotypes. In summary, glucose tolerance was deteriorated by HSD and HFD, with HFD exerting an earlier and stronger effect and APP23 mice being less affected. Moreover, HSD and HFD increased fasting glucose levels, but only HFD elevated fasting insulin levels, both parameters being similar across genotypes.

### **APP23 mice showed increased O<sub>2</sub> consumption, CO<sub>2</sub> production, energy expenditure, and locomotor activity at night**

To further investigate whole-body metabolism of APP23 mice, indirect calorimetry was performed at baseline, week 12 and 20. Figure 6 (statistics see Supplementary Table 3) depicts results measured during active phase. Light phase data are displayed in Supplementary Figure 1. O<sub>2</sub> consumption and CO<sub>2</sub> production adjusted for lean mass were increased in APP23 mice at any time-point. Measurements adjusted for body weight were similar (Supplementary Figure 2). On closer examination, APP23 mice consumed 12% more O<sub>2</sub> at baseline (Figure 6A) and up to 22% in week 12 and 20 (Figure 6B, 6C). Diet alone did not affect O<sub>2</sub> consumption at any time-point. Correspondingly, CO<sub>2</sub> production was 10% elevated in APP23 mice at baseline (Figure 6D) and up to 14% in week 12 and 20 (Figure 6E, 6F). Contrary to O<sub>2</sub> consumption, CO<sub>2</sub> production was affected by diet, such as HFD-fed mice produced up to 22% less CO<sub>2</sub> compared to NCD/HSD at both time-points. The respiratory exchange ratio was similar between genotypes at baseline (Figure 6G). During HSD, it decreased up to 10% in APP23 mice at both time-points (Figure 6H, 6I), while no genotype differences were observed during NCD and HFD. HSD increased the respiratory exchange ratio, however only




**Figure 4. Analysis of basic metabolic parameters in blood of fed mice.** (A–C) Plasma insulin measured in NCD-fed (A), HSD-fed (B) and HFD-fed (C) mice at baseline (week 0) and after 4, 8, 12, 16, and 20 weeks of diet. Corticosterone levels (D) and NEFA levels (E) measured in blood plasma obtained upon sacrifice after 20 weeks of diet. Data are represented as box (25<sup>th</sup> to 75<sup>th</sup> percentile) with median and whiskers from minimum to maximum. Black asterisks indicate significant differences between groups (\*:  $p < 0.05$ ; \*\*:  $p < 0.01$ ; \*\*\*:  $p < 0.001$ ), gray asterisk indicates a statistical trend towards significance ( $p < 0.1$ ) according to Tukey post-hoc test of repeated measures ANOVA (A–C) and nonparametric multiple contrast Tukey-type test (D, E).  $n_{\text{NCD WT}}=15$ ,  $n_{\text{NCD APP23}}=9$ ,  $n_{\text{HSD WT}}=10$ ,  $n_{\text{HSD APP23}}=14$ ,  $n_{\text{HFD WT}}=10$ ,  $n_{\text{HFD APP23}}=10$ .



**Figure 5. Acute glucose handling and fasting glucose homeostasis after 12 (left column) and 20 weeks (right column) of dietary interventions in APP23 and WT mice.** (A, B) Course of blood glucose in an intraperitoneal glucose tolerance test (ipGTT) after 12 (A) and 20 weeks (B) and the corresponding area under the curve (AUC) (C, D). The corresponding basal blood glucose (E, F) and insulin levels (G, H) of WT and APP23 mice were analyzed after 6 h of fasting in the morning. Data are represented as box (25<sup>th</sup> to 75<sup>th</sup> percentile) with median and whiskers from minimum to maximum. Black asterisks indicate significant differences between groups (\*:  $p < 0.05$ ; \*\*:  $p < 0.01$ ; \*\*\*:  $p < 0.001$ ), gray asterisk indicates a statistical trend towards significance ( $p < 0.1$ ) according to nonparametric ANOVA-type statistics (A, B) ordinary 2-way ANOVA with Tukey post-hoc test (C, D) or nonparametric multiple contrast Tukey-type test (E–H).  $n_{\text{NCD WT}}=15$ ,  $n_{\text{NCD APP23}}=9$ ,  $n_{\text{HSD WT}}=10$ ,  $n_{\text{HSD APP23}}=14$ ,  $n_{\text{HFD WT}}=10$ ,  $n_{\text{HFD APP23}}=10$ .





**Figure 6. O<sub>2</sub> consumption, CO<sub>2</sub> production, respiratory exchange ratio, energy expenditure, and activity during active phase at baseline (left column), after 12 (middle column) and 20 weeks of diet (right column).** (A–C) Averaged O<sub>2</sub> consumption per hour and (D–F) averaged CO<sub>2</sub> production per hour (both adjusted for lean mass) as well as (G–I) corresponding mean respiratory exchange ratio. (J–L) Averaged energy expenditure per hour correlated with lean mass and (M–O) averaged locomotor activity per hour. Data are represented as box (25<sup>th</sup> to 75<sup>th</sup> percentile) with median and whiskers from minimum to maximum. Black asterisks indicate significant differences between groups (\*: p<0.05; \*\*: p<0.01; \*\*\*: p<0.001), gray asterisk indicates a statistical trend towards significance (p<0.1) according to nonparametric t-tests (A, D, G, M), nonparametric multiple contrast Tukey-type test (B, C, E, F, H, I, N, O), and Spearman correlation followed by ANCOVA (J–L). n<sub>NCD WT</sub>=15, n<sub>NCD APP23</sub>=9, n<sub>HSD WT</sub>=10, n<sub>HSD APP23</sub>=14, n<sub>HFD WT</sub>=10, n<sub>HFD APP23</sub>=10.

in WT mice and week 20, whereas HFD decreased it up to 16% in both genotypes at both time-points.

Next, we evaluated energy expenditure and activity. To account for the major contribution of body weight, energy expenditure was correlated with lean mass (Figure 6J–6L and Supplementary Figure 1J–1L) or body weight (Supplementary Figure 2G–2I, 2P–2R; correlation statistics see Supplementary Table 4). Since diet alone did not affect energy expenditure, different dietary groups were pooled. APP23 mice showed 11% elevated energy expenditure compared to WT mice at baseline ( $F(1,58)=15.488$ ,  $p<0.001$  lean mass-corrected; Figure 6J), 9% in week 12 ( $F(1,63)=51.102$ ,  $p<0.001$  lean mass-corrected; Figure 6K) and 10% in week 20 ( $F(1,65)=21.948$ ,  $p<0.001$  lean mass-corrected; Figure 6L). Supplementary Figure 3 shows energy expenditure over the course of 24 h revealing a constantly increased energy expenditure of APP23 mice, especially pronounced during dark phase. Correspondingly, APP23 mice were 38% more active than WT mice at baseline (Figure 6M) and up to 84% and 71% in week 12 and 20 (Figure 6N, 6O). HFD feeding decreased locomotor activity up to 60% compared to NCD/HSD in both genotypes at both time-points.

Altogether, APP23 mice showed notably higher  $O_2$  consumption,  $CO_2$  production, and energy expenditure as well as increased activity. The effects of diet were mild and mainly represented by an HFD-induced reduction of activity and – as expected – of the respiratory exchange ratio.

### **Proteome analyses indicated potential mitochondrial dysfunction of APP23 mice**


To investigate metabolic alterations in APP23 mice on protein level, we performed proteome analyses in liver (Figure 7) and brain (Supplementary Figure 4). Liver proteome profiles showed a genotype-clustering within NCD- and HSD-fed mice but a genotype-overlapping clustering within HFD-fed mice. (Figure 7A). Volcano plots displayed several differentially regulated proteins in APP23 mice, especially involved in lipid metabolism (CYP39A1, SDR39U1, AAMDC, FTO, ACOT8, VASP), oxidative phosphorylation,  $\beta$ -oxidation and general mitochondrial function (TBRG4, SCO2, MPV17, MRPL12, NDUFB2, NUBBPL, GLRX5, TIMM13, NFU1, COX5A, SCO1, CYP3A16, PDK4) or related to inflammation and metabolic stress (PRKAA2, SERPINB1A, TMEM258, LGALS3; Figure 7B–7D). Some mitochondria-related proteins were also differentially regulated in brain proteome of APP23 mice (MCEE, ADCK1) but the majority is involved in signal transduction, vesicle trafficking, synaptic function and neuronal plasticity (SYT17, DIP2A,

BLOC1S1, SNCB, BAIAP3, WDR11, KCNIP3, TRAPPC13; Supplementary Figure 4). Simulation of metabolic capacities showed only minor differences in hepatic glucose tolerance. NCD-fed APP23 mice had slightly better glucose tolerance at low external glucose, while their glucose tolerance was slightly inferior at high external glucose ( $F(9,90)=2.710$ ,  $p=0.008$ ), contrary during HSD ( $F(9,90)=5.750$ ,  $p<0.001$ ) and without difference during HFD (Figure 7E–7G). NEFA tolerance seemed to be slightly decreased in NCD- and HSD-fed APP23 mice (n.s.; Figure 7H–7J). Gene Set Enrichment Analysis (GSEA) revealed downregulation of protein sets affecting lipid metabolism, oxidative phosphorylation, and mitochondrial function in NCD-fed APP23 mice (Figure 7K). Interestingly, the same protein sets were upregulated in HSD-fed APP23 mice but unchanged in HFD-fed APP23 mice. Instead, protein sets contributing to translation and amino acid metabolism were downregulated.

## **DISCUSSION**

Involuntary weight loss advances with AD progression resulting in poorer health, reduced quality of life, and increased mortality [14]. Thus, identifying the role of (reduced) body weight in AD might contribute to the understanding of metabolic implications in AD pathogenesis. Therefore, we investigated APP23 mice during diet-induced metabolic challenge. To our knowledge, this is the first longitudinal study assessing metabolic features of APP23 females, revealing lower body weight, less adipocyte hypertrophy as well as steatosis, elevated energy expenditure as well as activity and evidence for potential mitochondrial damage.

A lower body weight already emerges in 4-week old APP23 mice due to lower lean mass, whereas plaque development starts around 6 months of age [20]. However, lower body weight of APP23 mice did not result from smaller body length, which was also reported for 24-months old APP23 females [21]. Although APP23 mice do not model AD-related weight loss, their lower body weight at a pre-plaque stage corresponds to lower body weight of AD patients, which arises from early weight loss prior to the onset of clinical AD symptoms [16, 22]. Consistent with literature, HSD induced a mild, but HFD a substantial body weight gain [19, 23–25], in which APP23 mice gained less fat mass. Analysis of food intake as a potential mechanism for lower body weight revealed lower HFD consumption, contradicting a study in APP23 males reporting increased food intake [26]. However, estrogen might have influenced food intake via its interaction with leptin [27], counterbalancing food intake in APP23 females. HFD contains less carbohydrates than NCD and HSD but similar amounts



**Figure 7. Proteome analyses of liver tissue.** (A) Heatmap of differentially regulated proteins (B–D) Volcano plots of APP23 versus WT mice within each diet. (E–G) Simulated hepatic glucose tolerance of APP23 versus WT mice within each diet. (H–J) Simulated hepatic NEFA tolerance of APP23 versus WT mice within each diet. (K) GSEA of APP23 versus WT mice within each diet. (B, E, H) NCD; (C, F, I) HSD; (D, G, J) HFD. n=6 each.

of protein, which may explain the increased HFD-intake of WT mice, as mice adapt their food intake to a favored low protein/high carbohydrate ratio even by overeating [28]. In contrast, food intake of APP23 mice remained constant regardless of diet suggesting potential alterations of nutrient-specific feedback mechanisms. This is corroborated by a study in Tg2576 mice (same *App* mutation/different promoter) revealing dysfunctional hypothalamic leptin signaling depicted by decreased leptin levels [29]. The fact that hyperactivity and increased energy expenditure of APP23 mice were not compensated by higher food intake, as one could have expected [30], also suggests a dysregulation of energy balance. Since the hypothalamus plays a crucial role in regulating food intake and energy balance [31], altered nutrient-specific feedback and lacking compensatory hyperphagia in APP23 mice might be caused by altered hypothalamic leptin signaling [32]. Altogether, although APP23 mice displayed only reduced food intake during HFD, compensatory hyperphagia to account for increased energy expenditure was not observed during any diet and, thus, potentially contributing to lower body weight of APP23 mice. As a potential underlying mechanism, hypothalamic leptin signaling in APP23 mice deserves further investigations.

Necropsy showed that while HSD induced mild liver weight gain only in WT mice, HFD induced substantial liver weight gain in both genotypes. Histology and triglyceride quantification revealed progressive steatosis, however diminished in APP23 mice, especially during HFD. The lower degree of steatosis in APP23 mice corresponds to their lower body weight. Indeed, it has been shown in weight loss experiments that body weight strongly influences the extent of hepatic steatosis [33]. Furthermore, steatosis considerably contributes to insulin resistance via hepatic inflammation [34]. Actually, the degree of steatosis was to some extent reflected in insulin levels: HFD-fed WT mice showed the most prominent steatosis accompanied by the most prominent elevation of insulin levels, while the lower extent of steatosis in HFD-fed APP23 mice might contribute to a less prominent insulin resistance. HSD related body weight gain and the corresponding degree of steatosis might not be sufficient to induce insulin resistance. Consistently, only HFD but not HSD elevated eWAT weight. Adipocyte size gradually increased from NCD to HFD, APP23 mice exhibiting less hypertrophy. Hypertrophic instead of hyperplastic adipose tissue expansion indicates metabolic disease [35]. Thus, HSD-induced hypertrophy without increased fat mass suggests an incipient metabolic dysfunction.

We longitudinally monitored glycemic control via fed insulin concentrations. Gradually increasing insulin

levels during HFD indicate a compensation of beginning insulin resistance via higher insulin secretion to maintain physiological glucose levels. As insulin sensitivity is strongly correlated with body weight [36], lower body weight of APP23 mice together with the lesser degree of steatosis potentially accounts for lower insulin levels in HFD-fed APP23 mice suggesting superior insulin sensitivity. Furthermore, we examined corticosterone as a functional antagonist of insulin and NEFA as a correlate for lipolysis. Corticosterone levels were similar between genotypes as already described [19], possibly due to young age and low A $\beta$  load of APP23 mice [37]. NEFA levels were unaltered by genotype but reduced by HFD, potentially due to the lipolysis-inhibiting effect of elevated insulin levels [38]. This observation rather points to a still physiological insulin sensitivity, as obesity and insulin resistance lead to increased lipolysis [39]. Additionally, fasting glucose and insulin levels were unaltered in APP23 mice.

Although reduced brain glucose metabolism occurs early in AD progression [40], peripheral glycemic dysfunction is under debate and was not observed in APP23 mice. Evidence suggests that glycemic dysregulation in AD might be mediated by peripheral A $\beta$  [41], which is low in APP23 mice [42]. Together with lower body weight and less steatosis this might account for an even slightly superior peripheral metabolism supporting current literature [43]. HFD considerably deteriorated glucose tolerance already after 12 weeks potentially via a combination of elevated hepatic and adipose tissue inflammation, lipid overload and hypothalamic alterations [44]. HSD aggravated glucose tolerance only moderately after 20 weeks, possibly due to the scarce effect on body weight considering obesity a major contributor to glucose intolerance.

To further investigate mechanisms underlying lower body weight of APP23 mice, indirect calorimetry was evaluated. We showed for the first time that APP23 mice consumed notably more O<sub>2</sub> and produced notably more CO<sub>2</sub>, indicating an increased metabolic rate even before A $\beta$  plaque development. This finding confirms a study in pre-plaque Tg2576 mice with increased O<sub>2</sub> consumption also at rest [29]. Interestingly, the respiratory exchange ratio of NCD- and HSD-fed APP23 mice was decreased, suggesting a tendency towards fat instead of carbohydrates burning, potentially contributing to lower body weight and adiposity in APP23 mice. Furthermore, energy expenditure was elevated in APP23 mice, accompanied by hyperactivity. Hyperactivity has previously been observed in APP23 males, especially towards the end of the active phase, potentially reflecting so-called sundowning behavior of AD patients [45]. Whereas



energy expenditure was unaffected by diet, activity was reduced during HFD as described [46]. The finding that HFD reduced activity but not energy expenditure and O<sub>2</sub> consumption, suggests that elevated energy expenditure of APP23 mice might not solely depend on increased activity. Altogether, this indicates that increased O<sub>2</sub> consumption, CO<sub>2</sub> production, and energy expenditure of APP23 mice are probably not only caused by hyperactivity but additionally by an increased resting metabolic rate.

Interestingly, our proteome analyses imply a mitochondrial dysfunction of APP23 mice. Studies indicate that dysfunctions of cerebral mitochondria, potentially induced by A $\beta$ , might play a central role in AD pathogenesis [47]. Earlier proteome studies in APP23 brains revealed altered expression of proteins associated with glycolysis and oxidative phosphorylation as well as increased oxidative stress represented by a higher proportion of carbonylated proteins [48]. We also report alterations in mitochondria-related proteins in brain tissue. Even more interesting, we observed very similar modifications in liver tissue, revealing differential expression of proteins involved in oxidative phosphorylation,  $\beta$ -oxidation, and metabolic stress. Hence, our data might indicate a general mitochondrial dysfunction in APP23 mice not only limited to neurons. Notably, this dysfunction seems to be counterbalanced by HSD, potentially due to massive substrate provision (i.e. sucrose) possibly stimulating mitochondrial pathways. It has been shown previously that HSD induces overexpression of specific mitochondrial proteins in hepatocytes and increases the mitochondrial production of reactive oxygen species [49]. This reaction – normally a sign of oxidative stress – might be beneficial in HSD-fed APP23 mice to compensate for mitochondrial dysfunction represented by downregulated mitochondrial proteins in NCD-fed APP23 mice. This is in line with slightly inferior hepatic glucose tolerance in NCD-fed APP23 mice compared to slightly superior hepatic glucose tolerance in HSD-fed APP23 mice. As HFD and hepatic steatosis have been shown to induce oxidative stress and mitochondrial damage [50], we assumed a differential regulation of mitochondrial pathways in HFD-fed mice, however, found no such evidence. Moreover, a transcriptome analysis of HFD-fed APP23 brains has shown higher expression of genes involved in immune response and inflammation due to HFD [25], which was not obvious in our brain tissue on protein level. However, mice in the mentioned study were 12-months old, thus potentially being more prone to inflammation due to their advanced plaque pathology.

In summary, this study is the first to systematically analyze lower body weight of pre-plaque APP23 mice,

extensively characterizing metabolic features of this murine AD model. Although our data is descriptive, we conclude that lower body weight of APP23 mice is most likely caused by a combination of hyperactivity, increased metabolism, and dysregulated energy balance reflected by the absence of compensatory feeding mechanisms. Furthermore, we found evidence of dysfunctional mitochondrial pathways not only in the brain but for the first time also in the liver. These findings are highly interesting with regard to emerging hypotheses about the implication of mitochondrial dysfunction in AD pathogenesis. Both, mitochondrial dysfunction as well as altered hypothalamic leptin signaling deserve further research as they might underlie the described metabolic changes in APP23 females. Interestingly, lower body weight of APP23 mice may partially protect from diet-induced metabolic stress depicted by extenuated steatosis and adipocyte hypertrophy, which seem to contribute to improved insulin sensitivity. As the translation of basic animal research into the clinic is challenging, we strongly encourage thorough metabolic investigation of AD patients to contribute to the understanding of metabolic implications in AD pathogenesis.

## MATERIALS AND METHODS

### Ethics statement

This study was approved by the local animal ethics committee (LAGeSo Berlin; G0074/16) and carried out in accordance with EU Directive 10/63/EU as well as in line with the ARRIVE guidelines.

### Animal experiments

The study was conducted in 33 female transgenic APP23 mice (APP23) and 35 female healthy littermates (WT) on a C57BL/6J background. APP23 mice overexpress human APP<sub>751</sub> cDNA with the Swedish double mutation under the murine Thy-1 promotor [20]. A $\beta$  plaque deposition starts at 6 months of age [20]. Mice were group-housed (2-3/cage) in environmentally controlled, individually ventilated cages (21.5° C $\pm$ 1.5) with a 12-hour light/dark cycle and ad libitum access to food and water. 4-6-week old mice were randomly allocated to normal-control (NCD), high-sucrose (HSD) or high-fat diet (HFD; all Research Diets) for 20 weeks (Figure 1B and Supplementary Table 1). Body weight and food intake were recorded weekly (Figure 1A). Body length was exemplarily measured from tip of the nose to tail root in a separate set of young adult mice (8-11-week old female and male APP23 (n=11, thereof 4 females) and WT mice (n=8, thereof 2 females)). Monthly, body composition was measured by <sup>1</sup>H-magnetic-resonance-



spectroscopy (NMR) using a Minispec LF50 (Bruker) and blood was collected from *Vena facialis* in the morning. Serum was stored at  $-80^{\circ}\text{C}$  for analysis of insulin levels. Indirect calorimetry and activity were analyzed in single-caged mice (LabMaster-System, TSE) for 48 h (12 h adaption/36 h evaluation: 1 light and mean of 2 dark phases) in week 0, 12, and 20. Intraperitoneal (i.p.) glucose tolerance tests (ipGTT) were performed in week 12 and 20 after a 6 h morning-fast and local analgesia of tail tip (lidocaine/prilocain, AstraZeneca). Glucose levels were measured in duplicates (Contour Next, Bayer) before (0 min), 15, 30, 60, and 120 min after injection of 2 g/kg body weight glucose. At 0 min, plasma was additionally collected and stored at  $-80^{\circ}\text{C}$  for analysis of fasting insulin levels. Terminally, mice were sacrificed as described [19]. Plasma was stored at  $-80^{\circ}\text{C}$ . Tissues were stored partially snap-frozen ( $-80^{\circ}\text{C}$ ) and partially in 4% PFA/PBS ( $4^{\circ}\text{C}$ ).

### Histology and immunohistochemistry

PFA-fixed livers were transferred in O.C.T. Compound (Sakura) and 5  $\mu\text{m}$  sections were cryocut using a Jung Frigocut 2800E (Leica). eWAT was dehydrated, infiltrated and embedded with paraffin and 5  $\mu\text{m}$  sections were cut using a Microm Cool-Cut HM 325 (ThermoFisher).

eWAT and liver sections were stained with hematoxylin/eosin and Oil Red O, respectively, as described [51]. Hematoxylin/eosin-stained eWAT (4 sections of 6 random mice/genotype/diet) and Oil Red O-stained liver (4 sections of 8 random mice/genotype/diet) were recorded with 20x on a BZ-9000 microscope (Keyence). Average adipocyte size and mean percentage Oil Red O-covered area were analyzed with ImageJ (V1.52a).

### Biochemical analyses

Triglycerides were quantified in liver tissue (6 random mice/genotype/diet). Frozen liver ( $\sim 60$  mg) was suspended in 600  $\mu\text{l}$  alcoholic KOH and incubated at  $60^{\circ}\text{C}$  for 6 h. 540  $\mu\text{l}$  1M  $\text{MgCl}_2$  were added to 500  $\mu\text{l}$  of the saponificated sample, followed by 10 min incubation on ice and 30 min centrifugation at full speed. Supernatant was collected and analyzed according to manufacturer instructions using the Triglycerides FS 10' kit (Diagnostic Systems). Triglyceride concentrations were multiplied by actual liver weight measured upon sacrifice to obtain absolute values.

Fed insulin was quantified in serum and fasting insulin in plasma using the Mouse Insulin ELISA kit (Mercodia). Corticosterone and NEFAs were measured

in final plasma using the Corticosterone ELISA kit (IBL International) and the NEFA-HR(2) kit (Wako).

### Proteomics

Frozen whole-brain (350-450 mg, 4 random mice/genotype/diet) was prepared and homogenized. 18-55 mg were used for lysates, 30  $\mu\text{g}$  digested and 1  $\mu\text{g}$  was analyzed using nano-LC-MS/MS as described [52, 53]. Data were processed with MaxQuant (V1.6.0.1) [54] and searched against mouse UniProtKB with 21,074 entries, released 12/2018.

Frozen liver ( $\sim 5$ mg, 6 random mice/genotype/diet) was suspended in 75  $\mu\text{l}$  lysis buffer (1% SDS/100 mM ABC+1.25x PIC), sonicated twice (Covaris ML230: PIP 375 W, DF 25%, CPB 50, 20 repeats, 10 s pulse, 10 s delay, 12 C, dither 3 mm Y-axis) and insoluble particles were removed by centrifugation. 15  $\mu\text{l}$  lysate was adjusted to 50  $\mu\text{l}$  with water and processed on a Biomek i7 workstation using protocol SP3 [55]. On a two-column-system 1.25  $\mu\text{g}$  tryptic peptides were analyzed by LC-MS/MS [53]. Separation was done by applying a gradient from 7.5% to 55% B in 120 min at a flow rate of 300 nL/min (solvent A: 0.1% formic acid in water; solvent B: 80% acetonitrile and 0.1% formic acid). The Orbitrap was configured to acquire  $25 \times 24$  m/z (covering 400-1000 m/z), precursor isolation window data independent acquisition (DIA) spectra (17,500 resolution, AGC target  $1e6$ , maximum inject time 60ms, normalized HCD collision energy 27%) using overlapping windows. A full scan MS spectra (m/z 400-1000) was recorded at 35,000 resolution after 60 ms accumulation of ions to a  $1e6$  target value in profile mode. Raw data were processed using DIA-NN 1.7.12 [56], scan window size set to 14 and MS2 and MS1 mass accuracies to 20 and 10 ppm, respectively. A project-independent public spectral library [57] and mouse UniProt (UP000000589) were used for annotation. The library was automatically refined based on the dataset, global  $q=0.01$  (using the "Generate spectral library" option in DIA-NN) [58].

### Modeling of metabolic capacities

Metabolic capabilities of individual mice were evaluated using an established kinetic model of the energy metabolism of hepatic and neuronal cells encompassing glycolysis, citric acid cycle, the respiratory chain and oxidative phosphorylation [59, 60]. This model describes the dynamic of metabolites and fluxes via ordinary differential equations taking into account the regulatory properties of the underlying metabolic enzymes, such as substrate affinities ( $K_m$ -values), allosteric properties ( $K_i$ -values and  $K_a$ -values) and alterations in these parameters due to

phosphorylation (interconversion). It distinguished between different cellular compartments (cytosol, mitochondria, endoplasmic reticulum). As maximal enzyme activity is proportional to protein abundance, individualized models were generated scaling the maximal enzyme activities ( $V_{\max}$ ) of each metabolic enzyme and transporter by the relation

$$V_{\max}^{\text{animal}} = V_{\max}^{\text{control}} \cdot \frac{E^{\text{animal}}}{E^{\text{control}}}, \text{ where } E^{\text{control}} \text{ is the average}$$

enzyme intensity in all controls and  $E^{\text{animal}}$  is the enzyme concentration in the individual animal. Metabolic capacities were simulated by systemic variation of the external conditions (plasma nutrient and hormone composition). Hepatic glucose exchange flux was simulated by simultaneous variation of plasma glucose concentration, plasma free fatty acid concentration and plasma insulin and glucagon concentrations as in [59, 61, 62]. MATLAB (Release2012a; optimization toolbox) was used for simulations and respective graphs.

## Statistics

Data are represented as boxes (25<sup>th</sup> to 75<sup>th</sup> percentile) with median and min/max-whiskers or as mean with standard deviation. SPSS Statistics (V25), GraphPad Prism (V8), and R (V3.6.3; packages nparcomp, nparLD, car, DEP, clusterProfiler) were used for statistics and graphs.

MS output was filtered (FDR=0.01) at peptide level and for completeness in at least one experimental group, missing values were imputed and all contrasts between experimental groups were analyzed for differentially expressed proteins ( $\alpha \leq 0.05$ , absolute  $\log_2$  fold-change  $\geq 1$ ). Volcano plots and heatmaps were automatically generated. For GSEA, data were mapped to the human annotation and biological processes from the gene ontology database were selected. Results were filtered (20-500 gene set size,  $q \leq 0.01$ ) and the top-10 enriched terms per contrast and direction were plotted.

Shapiro-Wilk test for normal distribution and Levene's test for equality of variances were applied. If passed, 2-way ANOVA (ordinary/repeated measures) with Tukey post-hoc test was performed. Otherwise, nonparametric t-test, nonparametric multiple contrast test type Tukey, or nonparametric (repeated measures) ANOVA-type statistics were chosen. According to [63], ANCOVA was performed for analysis of pooled energy expenditure data to correct for lean mass-/body weight-effects. Therefore, equality of slopes was checked by simple linear regression before pooling dietary groups in a first step, energy expenditure was correlated with lean mass/body weight using Spearman correlation in a second step and finally ANCOVA was performed.

Significance was considered \* $p \leq 0.05$ , \*\* $p \leq 0.01$ , \*\*\* $p \leq 0.001$ , trends towards significance ( $p < 0.1$ ) are displayed in gray. No data were excluded from any analysis.

## Data availability

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

## Abbreviations

APP23: transgenic mouse model; AD: Alzheimer's disease; AUC: area under the curve; BL: blood withdrawal; BW: body weight; EE: energy expenditure; eWAT: epigonadal white adipose tissue; GSEA: gene set enrichment analysis; GTT: glucose tolerance test; HFD: high-fat diet; HSD: high-sucrose diet; i.p.: intraperitoneal; LM: LabMaster; MS: mass spectrometry; NCD: normal-control diet; NEFA: non-esterified free fatty acids; n.s.: non-significant; RER: respiratory exchange ratio; WT: wild type control littermates.

## AUTHOR CONTRIBUTIONS

S. S.: Conceptualization, Methodology, Investigation, Formal analysis, Visualization, Writing - original draft, Funding acquisition. N. B.: Software, Formal analysis. J. E.: Software, Formal analysis. M. M.: Methodology, Investigation Software, Formal analysis, Visualization. S. H.-S.: Writing - review and editing. C. K.: Conceptualization, Writing - review and editing. B. A.: Investigation. A. P.: Investigation, Writing - review and editing. D. M.: Investigation, Resources. J. S.: Resources, Funding acquisition, Writing - review and editing. B. S.: Resources, Funding acquisition, Project administration, Writing - review and editing. S. B.: Conceptualization, Methodology, Investigation, Formal analysis, Resources, Funding acquisition, Supervision, Writing - review and editing.

## ACKNOWLEDGMENTS

The authors thank Diana Woellner, Marie-Christin Gaerz, Nadine Huckauf, and Candy Kalischke (Charité – Universitätsmedizin Berlin) for excellent assistance with mouse and biochemical experiments, as well as Beata Lukaszewska-McGreal (Max Planck Institute for Molecular Genetics) and Dr. Kathrin Textoris-Taube (High Throughput Mass Spectrometry Core Facility of Charité – Universitätsmedizin Berlin) for brain and liver proteome sample preparation and measurements. Proteome analyses for brain were conducted at Max Planck Institute for Molecular

Genetics and for liver at the High Throughput Mass Spectrometry Core Facility of Charité – Universitätsmedizin Berlin.

Sebastian Brachs and Joachim Spranger are further associated with the Center for Cardiovascular Research (CCR) at the Charité – Universitätsmedizin Berlin, Hessische Straße 3-4, 10115 Berlin, Germany.

## CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

## FUNDING

This work was supported by the Department of Endocrinology and Metabolism, Charité – Universitätsmedizin Berlin, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK/BMBF), the Deutsche Diabetes Gesellschaft (DDG), and the Berlin Institute of Health (BIH). Stefanie Schreyer was granted the Elsa-Neumann-Scholarship of the state Berlin and the graduation scholarship of Charité – Universitätsmedizin Berlin. Johannes Eckstein was funded by “LiSyM” 31L0057 (BMBF). Furthermore, brain proteome analyses were funded by the Max Planck Society.

## REFERENCES

1. Korszyn AD. Why have we failed to cure Alzheimer's disease? *J Alzheimers Dis.* 2012; 29:275–82. <https://doi.org/10.3233/JAD-2011-110359> PMID:[22258512](https://pubmed.ncbi.nlm.nih.gov/22258512/)
2. Atri A. The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management. *Med Clin North Am.* 2019; 103:263–93. <https://doi.org/10.1016/j.mcna.2018.10.009> PMID:[30704681](https://pubmed.ncbi.nlm.nih.gov/30704681/)
3. Patterson C. World Alzheimer Report 2018. *Alzheimer's Dis Int.* 2018. <https://doi.org/10.1111/j.0033-0124.1950.24.14.x>
4. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. *Biochem Biophys Res Commun.* 1984; 120:885–90. [https://doi.org/10.1016/S0006-291X\(84\)80190-4](https://doi.org/10.1016/S0006-291X(84)80190-4) PMID:[6375662](https://pubmed.ncbi.nlm.nih.gov/6375662/)
5. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. *Proc Natl Acad Sci USA.* 1986; 83:4913–17. <https://doi.org/10.1073/pnas.83.13.4913> PMID:[3088567](https://pubmed.ncbi.nlm.nih.gov/3088567/)
6. Larson EB, Kukull WA, Katzman RL. Cognitive impairment: dementia and Alzheimer's disease. *Annu Rev Public Health.* 1992; 13:431–49. <https://doi.org/10.1146/annurev.pu.13.050192.002243> PMID:[1599598](https://pubmed.ncbi.nlm.nih.gov/1599598/)
7. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science.* 1992; 256:184–85. <https://doi.org/10.1126/science.1566067> PMID:[1566067](https://pubmed.ncbi.nlm.nih.gov/1566067/)
8. Foroutan N, Hopkins RB, Tarride JE, Florez ID, Levine M. Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer's disease: a systematic review and network meta-analysis. *Clin Invest Med.* 2019; 42:E53–65. <https://doi.org/10.25011/cim.v42i1.32393> PMID:[30904037](https://pubmed.ncbi.nlm.nih.gov/30904037/)
9. Li X, Song D, Leng SX. Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment. *Clin Interv Aging.* 2015; 10:549–60. <https://doi.org/10.2147/CIA.S74042> PMID:[25792818](https://pubmed.ncbi.nlm.nih.gov/25792818/)
10. Correia SC, Santos RX, Carvalho C, Cardoso S, Candeias E, Santos MS, Oliveira CR, Moreira PI. Insulin signaling, glucose metabolism and mitochondria: major players in Alzheimer's disease and diabetes interrelation. *Brain Res.* 2012; 1441:64–78. <https://doi.org/10.1016/j.brainres.2011.12.063> PMID:[22290178](https://pubmed.ncbi.nlm.nih.gov/22290178/)
11. de la Monte SM. Type 3 diabetes is sporadic Alzheimer's disease: mini-review. *Eur Neuropsychopharmacol.* 2014; 24:1954–60. <https://doi.org/10.1016/j.euroneuro.2014.06.008> PMID:[25088942](https://pubmed.ncbi.nlm.nih.gov/25088942/)
12. Emmerzaal TL, Kiliaan AJ, Gustafson DR. 2003-2013: a decade of body mass index, Alzheimer's disease, and dementia. *J Alzheimers Dis.* 2015; 43:739–55. <https://doi.org/10.3233/JAD-141086> PMID:[25147111](https://pubmed.ncbi.nlm.nih.gov/25147111/)
13. Power BD, Alfonso H, Flicker L, Hankey GJ, Yeap BB, Almeida OP. Changes in body mass in later life and incident dementia. *Int Psychogeriatr.* 2013; 25:467–78. <https://doi.org/10.1017/S1041610212001834> PMID:[23151427](https://pubmed.ncbi.nlm.nih.gov/23151427/)
14. Gillette Guyonnet S, Abellan Van Kan G, Alix E, Andrieu S, Belmin J, Berrut G, Bonnefoy M, Brocker P, Constans T, Ferry M, Ghisolfi-Marque A, Girard L, Gonthier R, et al, and International Academy on Nutrition and Aging Expert Group. IANA (International Academy on Nutrition and Aging)

- Expert Group: weight loss and Alzheimer's disease. *J Nutr Health Aging*. 2007; 11:38–48.  
PMID:[17315079](https://pubmed.ncbi.nlm.nih.gov/17315079/)
15. Cova I, Clerici F, Rossi A, Cucumo V, Ghiretti R, Maggiore L, Pomati S, Galimberti D, Scarpini E, Mariani C, Caracciolo B. Weight Loss Predicts Progression of Mild Cognitive Impairment to Alzheimer's Disease. *PLoS One*. 2016; 11:e0151710.  
<https://doi.org/10.1371/journal.pone.0151710>  
PMID:[26990757](https://pubmed.ncbi.nlm.nih.gov/26990757/)
  16. Johnson DK, Wilkins CH, Morris JC. Accelerated weight loss may precede diagnosis in Alzheimer disease. *Arch Neurol*. 2006; 63:1312–17.  
<https://doi.org/10.1001/archneur.63.9.1312>  
PMID:[16966511](https://pubmed.ncbi.nlm.nih.gov/16966511/)
  17. Ross R, Soni S, Houle SA. Negative Energy Balance Induced by Exercise or Diet: Effects on Visceral Adipose Tissue and Liver Fat. *Nutrients*. 2020; 12:891.  
<https://doi.org/10.3390/nu12040891>  
PMID:[32218121](https://pubmed.ncbi.nlm.nih.gov/32218121/)
  18. Knight EM, Verkhatsky A, Luckman SM, Allan SM, Lawrence CB. Hypermetabolism in a triple-transgenic mouse model of Alzheimer's disease. *Neurobiol Aging*. 2012; 33:187–93.  
<https://doi.org/10.1016/j.neurobiolaging.2010.02.003>  
PMID:[20359775](https://pubmed.ncbi.nlm.nih.gov/20359775/)
  19. Schreyer S, Klein C, Pfeffer A, Rasińska J, Stahn L, Knuth K, Abuelnor B, Panzel AE, Rex A, Koch S, Hemmati-Sadeghi S, Steiner B. Chia seeds as a potential cognitive booster in the APP23 Alzheimer's disease model. *Sci Rep*. 2020; 10:18215.  
<https://doi.org/10.1038/s41598-020-75209-z>  
PMID:[33106576](https://pubmed.ncbi.nlm.nih.gov/33106576/)
  20. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Bürki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. *Proc Natl Acad Sci USA*. 1997; 94:13287–92.  
<https://doi.org/10.1073/pnas.94.24.13287>  
PMID:[9371838](https://pubmed.ncbi.nlm.nih.gov/9371838/)
  21. Lalonde R, Dumont M, Staufenbiel M, Strazielle C. Neurobehavioral characterization of APP23 transgenic mice with the SHIRPA primary screen. *Behav Brain Res*. 2005; 157:91–98.  
<https://doi.org/10.1016/j.bbr.2004.06.020>  
PMID:[15617775](https://pubmed.ncbi.nlm.nih.gov/15617775/)
  22. Stewart R, Masaki K, Xue QL, Peila R, Petrovitch H, White LR, Launer LJ. A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study. *Arch Neurol*. 2005; 62:55–60.  
<https://doi.org/10.1001/archneur.62.1.55>  
PMID:[15642850](https://pubmed.ncbi.nlm.nih.gov/15642850/)
  23. Yeh SH, Shie FS, Liu HK, Yao HH, Kao PC, Lee YH, Chen LM, Hsu SM, Chao LJ, Wu KW, Shiao YJ, Tsay HJ. A high-sucrose diet aggravates Alzheimer's disease pathology, attenuates hypothalamic leptin signaling, and impairs food-anticipatory activity in APP<sup>sw</sup>/PS1<sup>dE9</sup> mice. *Neurobiol Aging*. 2020; 90:60–74.  
<https://doi.org/10.1016/j.neurobiolaging.2019.11.018>  
PMID:[31879131](https://pubmed.ncbi.nlm.nih.gov/31879131/)
  24. Oliveira LS, Santos DA, Barbosa-da-Silva S, Mandarim-de-Lacerda CA, Aguila MB. The inflammatory profile and liver damage of a sucrose-rich diet in mice. *J Nutr Biochem*. 2014; 25:193–200.  
<https://doi.org/10.1016/j.jnutbio.2013.10.006>  
PMID:[24445044](https://pubmed.ncbi.nlm.nih.gov/24445044/)
  25. Nam KN, Mounier A, Wolfe CM, Fitz NF, Carter AY, Castranio EL, Kamboh HI, Reeves VL, Wang J, Han X, Schug J, Lefterov I, Koldamova R. Effect of high fat diet on phenotype, brain transcriptome and lipidome in Alzheimer's model mice. *Sci Rep*. 2017; 7:4307.  
<https://doi.org/10.1038/s41598-017-04412-2>  
PMID:[28655926](https://pubmed.ncbi.nlm.nih.gov/28655926/)
  26. Vloeberghs E, Van Dam D, Franck F, Serroyen J, Geert M, Staufenbiel M, De Deyn PP. Altered ingestive behavior, weight changes, and intact olfactory sense in an APP overexpression model. *Behav Neurosci*. 2008; 122:491–97.  
<https://doi.org/10.1037/0735-7044.122.3.491>  
PMID:[18513119](https://pubmed.ncbi.nlm.nih.gov/18513119/)
  27. Fungfuang W, Terada M, Komatsu N, Moon C, Saito TR. Effects of estrogen on food intake, serum leptin levels and leptin mRNA expression in adipose tissue of female rats. *Lab Anim Res*. 2013; 29:168–73.  
<https://doi.org/10.5625/lar.2013.29.3.168>  
PMID:[24106512](https://pubmed.ncbi.nlm.nih.gov/24106512/)
  28. Solon-Biet SM, McMahon AC, Ballard JW, Ruohonen K, Wu LE, Cogger VC, Warren A, Huang X, Pichaud N, Melvin RG, Gokarn R, Khalil M, Turner N, et al. The ratio of macronutrients, not caloric intake, dictates cardiometabolic health, aging, and longevity in ad libitum-fed mice. *Cell Metab*. 2014; 19:418–30.  
<https://doi.org/10.1016/j.cmet.2014.02.009>  
PMID:[24606899](https://pubmed.ncbi.nlm.nih.gov/24606899/)
  29. Ishii M, Wang G, Racchumi G, Dyke JP, Iadecola C. Transgenic mice overexpressing amyloid precursor protein exhibit early metabolic deficits and a pathologically low leptin state associated with hypothalamic dysfunction in arcuate neuropeptide Y neurons. *J Neurosci*. 2014; 34:9096–106.  
<https://doi.org/10.1523/JNEUROSCI.0872-14.2014>  
PMID:[24990930](https://pubmed.ncbi.nlm.nih.gov/24990930/)



30. Drenowatz C. Reciprocal Compensation to Changes in Dietary Intake and Energy Expenditure within the Concept of Energy Balance. *Adv Nutr.* 2015; 6:592–99. <https://doi.org/10.3945/an.115.008615> PMID:[26374181](https://pubmed.ncbi.nlm.nih.gov/26374181/)
31. Abdalla MM. Central and peripheral control of food intake. *Endocr Regul.* 2017; 51:52–70. <https://doi.org/10.1515/enr-2017-0006> PMID:[28222022](https://pubmed.ncbi.nlm.nih.gov/28222022/)
32. Xu AW, Kaelin CB, Morton GJ, Ogimoto K, Stanhope K, Graham J, Baskin DG, Havel P, Schwartz MW, Barsh GS. Effects of hypothalamic neurodegeneration on energy balance. *PLoS Biol.* 2005; 3:e415. <https://doi.org/10.1371/journal.pbio.0030415> PMID:[16296893](https://pubmed.ncbi.nlm.nih.gov/16296893/)
33. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. *Gastroenterology.* 2015; 149:367–78.e5. <https://doi.org/10.1053/j.gastro.2015.04.005> PMID:[25865049](https://pubmed.ncbi.nlm.nih.gov/25865049/)
34. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. *Nat Med.* 2005; 11:183–90. <https://doi.org/10.1038/nm1166> PMID:[15685173](https://pubmed.ncbi.nlm.nih.gov/15685173/)
35. Laforest S, Labrecque J, Michaud A, Cianflone K, Tchernof A. Adipocyte size as a determinant of metabolic disease and adipose tissue dysfunction. *Crit Rev Clin Lab Sci.* 2015; 52:301–13. <https://doi.org/10.3109/10408363.2015.1041582> PMID:[26292076](https://pubmed.ncbi.nlm.nih.gov/26292076/)
36. Clamp LD, Hume DJ, Lambert EV, Kroff J. Enhanced insulin sensitivity in successful, long-term weight loss maintainers compared with matched controls with no weight loss history. *Nutr Diabetes.* 2017; 7:e282. <https://doi.org/10.1038/nutd.2017.31> PMID:[28628125](https://pubmed.ncbi.nlm.nih.gov/28628125/)
37. Dong H, Yuede CM, Yoo HS, Martin MV, Deal C, Mace AG, Csernansky JG. Corticosterone and related receptor expression are associated with increased beta-amyloid plaques in isolated Tg2576 mice. *Neuroscience.* 2008; 155:154–63. <https://doi.org/10.1016/j.neuroscience.2008.05.017> PMID:[18571864](https://pubmed.ncbi.nlm.nih.gov/18571864/)
38. Stich V, Berlan M. Physiological regulation of NEFA availability: lipolysis pathway. *Proc Nutr Soc.* 2004; 63:369–74. <https://doi.org/10.1079/PNS2004350> PMID:[15294057](https://pubmed.ncbi.nlm.nih.gov/15294057/)
39. Arner P, Langin D. Lipolysis in lipid turnover, cancer cachexia, and obesity-induced insulin resistance. *Trends Endocrinol Metab.* 2014; 25:255–62. <https://doi.org/10.1016/j.tem.2014.03.002> PMID:[24731595](https://pubmed.ncbi.nlm.nih.gov/24731595/)
40. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. *FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging.* 2005; 32:486–510. <https://doi.org/10.1007/s00259-005-1762-7> PMID:[15747152](https://pubmed.ncbi.nlm.nih.gov/15747152/)
41. Wijesekara N, Gonçalves RA, De Felice FG, Fraser PE. Impaired peripheral glucose homeostasis and Alzheimer’s disease. *Neuropharmacology.* 2018; 136:172–81. <https://doi.org/10.1016/j.neuropharm.2017.11.027> PMID:[29169962](https://pubmed.ncbi.nlm.nih.gov/29169962/)
42. Kuo YM, Beach TG, Sue LI, Scott S, Layne KJ, Kokjohn TA, Kalback WM, Luehrs DC, Vishnivetskaya TA, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Weller RO, Roher AE. The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease. *Mol Med.* 2001; 7:609–18. PMID:[11778650](https://pubmed.ncbi.nlm.nih.gov/11778650/)
43. Lin B, Hasegawa Y, Takane K, Koibuchi N, Cao C, Kim-Mitsuyama S. High-Fat-Diet Intake Enhances Cerebral Amyloid Angiopathy and Cognitive Impairment in a Mouse Model of Alzheimer’s Disease, Independently of Metabolic Disorders. *J Am Heart Assoc.* 2016; 5:e003154. <https://doi.org/10.1161/JAHA.115.003154> PMID:[27412896](https://pubmed.ncbi.nlm.nih.gov/27412896/)
44. Williams LM, Campbell FM, Drew JE, Koch C, Hoggard N, Rees WD, Kamolrat T, Thi Ngo H, Steffensen IL, Gray SR, Tups A. The development of diet-induced obesity and glucose intolerance in C57BL/6 mice on a high-fat diet consists of distinct phases. *PLoS One.* 2014; 9:e106159. <https://doi.org/10.1371/journal.pone.0106159> PMID:[25170916](https://pubmed.ncbi.nlm.nih.gov/25170916/)
45. Van Dam D, D’Hooge R, Staufenbiel M, Van Ginneken C, Van Meir F, De Deyn PP. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. *Eur J Neurosci.* 2003; 17:388–96. <https://doi.org/10.1046/j.1460-9568.2003.02444.x> PMID:[12542676](https://pubmed.ncbi.nlm.nih.gov/12542676/)
46. Bjursell M, Gerdin AK, Lelliott CJ, Egecioglu E, Elmgren A, Törnell J, Oscarsson J, Bohlooly-Y M. Acutely reduced locomotor activity is a major contributor to




- Western diet-induced obesity in mice. *Am J Physiol Endocrinol Metab.* 2008; 294:E251–60.  
<https://doi.org/10.1152/ajpendo.00401.2007>  
PMID:[18029443](https://pubmed.ncbi.nlm.nih.gov/18029443/)
47. Albensi BC. Dysfunction of mitochondria: Implications for Alzheimer's disease. *Int Rev Neurobiol.* 2019; 145:13–27.  
<https://doi.org/10.1016/bs.irn.2019.03.001>  
PMID:[31208523](https://pubmed.ncbi.nlm.nih.gov/31208523/)
48. Hartl D, Schuldt V, Forler S, Zabel C, Klose J, Rohe M. Presymptomatic alterations in energy metabolism and oxidative stress in the APP23 mouse model of Alzheimer disease. *J Proteome Res.* 2012; 11:3295–304.  
<https://doi.org/10.1021/pr300021e> PMID:[22568827](https://pubmed.ncbi.nlm.nih.gov/22568827/)
49. Ruiz-Ramírez A, Chávez-Salgado M, Peñeda-Flores JA, Zapata E, Masso F, El-Hafidi M. High-sucrose diet increases ROS generation, FFA accumulation, UCP2 level, and proton leak in liver mitochondria. *Am J Physiol Endocrinol Metab.* 2011; 301:E1198–207.  
<https://doi.org/10.1152/ajpendo.00631.2010>  
PMID:[21917631](https://pubmed.ncbi.nlm.nih.gov/21917631/)
50. Ajith TA. Role of mitochondria and mitochondria-targeted agents in non-alcoholic fatty liver disease. *Clin Exp Pharmacol Physiol.* 2018; 45:413–21.  
<https://doi.org/10.1111/1440-1681.12886>  
PMID:[29112771](https://pubmed.ncbi.nlm.nih.gov/29112771/)
51. Brachs S, Winkel AF, Tang H, Birkenfeld AL, Brunner B, Jahn-Hofmann K, Margerie D, Ruetten H, Schmoll D, Spranger J. Inhibition of citrate cotransporter Slc13a5/mINDY by RNAi improves hepatic insulin sensitivity and prevents diet-induced non-alcoholic fatty liver disease in mice. *Mol Metab.* 2016; 5:1072–82.  
<https://doi.org/10.1016/j.molmet.2016.08.004>  
PMID:[27818933](https://pubmed.ncbi.nlm.nih.gov/27818933/)
52. Guo J, Bertalan G, Meierhofer D, Klein C, Schreyer S, Steiner B, Wang S, Vieira da Silva R, Infante-Duarte C, Koch S, Boehm-Sturm P, Braun J, Sack I. Brain maturation is associated with increasing tissue stiffness and decreasing tissue fluidity. *Acta Biomater.* 2019; 99:433–42.  
<https://doi.org/10.1016/j.actbio.2019.08.036>  
PMID:[31449927](https://pubmed.ncbi.nlm.nih.gov/31449927/)
53. Gielisch I, Meierhofer D. Metabolome and proteome profiling of complex I deficiency induced by rotenone. *J Proteome Res.* 2015; 14:224–35.  
<https://doi.org/10.1021/pr500894v> PMID:[25361611](https://pubmed.ncbi.nlm.nih.gov/25361611/)
54. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat Biotechnol.* 2008; 26:1367–72.  
<https://doi.org/10.1038/nbt.1511>  
PMID:[19029910](https://pubmed.ncbi.nlm.nih.gov/19029910/)
55. Müller T, Kalxdorf M, Longuespée R, Kazdal DN, Stenzinger A, Krijgsveld J. Automated sample preparation with SP3 for low-input clinical proteomics. *Mol Syst Biol.* 2020; 16:e9111.  
<https://doi.org/10.15252/msb.20199111>  
PMID:[32129943](https://pubmed.ncbi.nlm.nih.gov/32129943/)
56. Demichev V, Messner CB, Vernardis SI, Lilley KS, Ralser M. DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput. *Nat Methods.* 2020; 17:41–44.  
<https://doi.org/10.1038/s41592-019-0638-x>  
PMID:[31768060](https://pubmed.ncbi.nlm.nih.gov/31768060/)
57. Krasny L, Bland P, Burns J, Lima NC, Harrison PT, Pacini L, Elms ML, Ning J, Martinez VG, Yu YR, Acton SE, Ho PC, Calvo F, et al. A mouse SWATH-mass spectrometry reference spectral library enables deconvolution of species-specific proteomic alterations in human tumour xenografts. *Dis Model Mech.* 2020; 13:dmm044586.  
<https://doi.org/10.1242/dmm.044586>  
PMID:[32493768](https://pubmed.ncbi.nlm.nih.gov/32493768/)
58. Messner CB, Demichev V, Wendisch D, Michalick L, White M, Freiwald A, Textoris-Taube K, Vernardis SI, Egger AS, Kreidl M, Ludwig D, Kilian C, Agostini F, et al. Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection. *Cell Syst.* 2020; 11:11–24.e4.  
<https://doi.org/10.1016/j.cels.2020.05.012>  
PMID:[32619549](https://pubmed.ncbi.nlm.nih.gov/32619549/)
59. Berndt N, Bulik S, Wallach I, Wünsch T, König M, Stockmann M, Meierhofer D, Holzhütter HG. HEPATOKIN1 is a biochemistry-based model of liver metabolism for applications in medicine and pharmacology. *Nat Commun.* 2018; 9:2386.  
<https://doi.org/10.1038/s41467-018-04720-9>  
PMID:[29921957](https://pubmed.ncbi.nlm.nih.gov/29921957/)
60. Berndt N, Kann O, Holzhütter HG. Physiology-based kinetic modeling of neuronal energy metabolism unravels the molecular basis of NAD(P)H fluorescence transients. *J Cereb Blood Flow Metab.* 2015; 35:1494–506.  
<https://doi.org/10.1038/jcbfm.2015.70>  
PMID:[25899300](https://pubmed.ncbi.nlm.nih.gov/25899300/)
61. Berndt N, Kolbe E, Gajowski R, Eckstein J, Ott F, Meierhofer D, Holzhütter HG, Matz-Soja M. Functional Consequences of Metabolic Zonation in Murine Livers: Insights for an Old Story. *Hepatology.* 2021; 73:795–810.  
<https://doi.org/10.1002/hep.31274>  
PMID:[32286709](https://pubmed.ncbi.nlm.nih.gov/32286709/)


62. Bulik S, Holzhütter HG, Berndt N. The relative importance of kinetic mechanisms and variable enzyme abundances for the regulation of hepatic glucose metabolism--insights from mathematical modeling. *BMC Biol.* 2016; 14:15.  
<https://doi.org/10.1186/s12915-016-0237-6>  
PMID:[26935066](https://pubmed.ncbi.nlm.nih.gov/26935066/)
63. Tschöp MH, Speakman JR, Arch JR, Auwerx J, Brüning JC, Chan L, Eckel RH, Farese RV Jr, Galgani JE, Hambly C, Herman MA, Horvath TL, Kahn BB, et al. A guide to analysis of mouse energy metabolism. *Nat Methods.* 2011; 9:57–63.  
<https://doi.org/10.1038/nmeth.1806>  
PMID:[22205519](https://pubmed.ncbi.nlm.nih.gov/22205519/)

SUPPLEMENTARY MATERIALS


Supplementary Figures



**Supplementary Figure 1. Oxygen (O<sub>2</sub>) consumption, carbon dioxide (CO<sub>2</sub>) production, respiratory exchange ratio (RER), energy expenditure (EE), and locomotor activity of mice measured in metabolic cages during the light (inactive) phase at baseline (left column) and after 12 (middle column) and 20 weeks of diet (right column). (A–C) Averaged O<sub>2</sub> consumption per hour and (D–F) averaged CO<sub>2</sub> production per hour (both adjusted for lean mass) as well as (G–I) corresponding mean RER at baseline (A, D, G), after 12 (B, E, H) and 20 weeks of intervention (C, F, I). (J–L) Averaged EE per hour correlated with lean mass and (M–O) averaged locomotor activity per hour at baseline (J, M) and after 12 (K, N) and 20 weeks of diet (L, O). Metabolic cage data was collected after 12 h adaption time during 36 h analysis (1 light and mean of 2 dark phases) with 2 cycles per hour. Date of light and dark phase were analyzed separately. Data are shown averaged per hour and except for RER and locomotor activity adjusted for lean mass. Data are represented as box (25<sup>th</sup> to 75<sup>th</sup> percentile) with median and whiskers from minimum to maximum. Black asterisks indicate significant differences between groups (\*: p < 0.05; \*\*: p < 0.01; \*\*\*: p < 0.001), gray asterisk indicates a statistical trend towards significance (p<0.1) according to nonparametric t-tests (A, D, G, J, M) or nonparametric multiple contrast Tukey-type test (B, C, E, F, H, I, K, L, N, O). Abbreviations: WT: wild type control; APP23: transgenic mouse model; NCD: normal-control diet; HSD: high-sucrose diet; HFD: high-fat diet; RER: respiratory exchange ratio; EE: energy expenditure.**




**Supplementary Figure 2. Oxygen ( $O_2$ ) consumption, carbon dioxide ( $CO_2$ ) production, and, energy expenditure (EE) of mice measured in metabolic cages during the light (inactive) and dark (active) phase at baseline (left column) and after 12 (middle column) and 20 weeks of diet (right column). (A–C) and (J–L) Averaged  $O_2$  consumption per hour adjusted for total BW during dark (active) phase (A–C) and during light (inactive) phase (J–L). (D–F) and (M–O) Averaged  $CO_2$  production per hour adjusted for total BW during dark (active) phase (D–F) and during light (inactive) phase (M–O). (G–I) and (P–R) Averaged EE per hour correlated with total BW during dark (active) phase (G–I) and during light (inactive) phase (P–R). Metabolic cage data was collected after 12 h adaption time during 36 h analysis (1 light and mean of 2 dark phases) with 2 cycles per hour. Date of light and dark phase were analyzed separately. Data are shown averaged per hour and except for RER and locomotor activity adjusted for lean mass. Data are represented as box (25<sup>th</sup> to 75<sup>th</sup> percentile) with median and whiskers from minimum to maximum. Black asterisks indicate significant differences between groups (\*:  $p < 0.05$ ; \*\*:  $p < 0.01$ ; \*\*\*:  $p < 0.001$ ), gray asterisk indicates a statistical trend towards significance ( $p < 0.1$ ) according to nonparametric t-tests (A, D, G, J, M) or nonparametric multiple contrast Tukey-type test (B, C, E, F, H, I, K, L, N, O). Abbreviations: WT: wild type control; APP23: transgenic mouse model; NCD: normal-control diet; HSD: high-sucrose diet; HFD: high-fat diet; EE: energy expenditure.**



**Supplementary Figure 3. Energy expenditure (EE) over the course of 24 hours (one light, one dark phase) at baseline (left column) and after 12 (middle column) and 20 weeks of diet (right column).** Upper panel: Energy expenditure corrected for total body weight (BW). Lower panel: Energy expenditure corrected for lean mass. APP23 mice showed increased EE compared to WT regardless of time-point and diet. Data are represented as mean with standard deviation. Repeated measures 2-way ANOVA was performed. Abbreviations: WT: wild type control; APP23: transgenic mouse model; NCD: normal-control diet; HSD: high-sucrose diet; HFD: high-fat diet; BW: body weight; EE: energy expenditure.





**Supplementary Figure 4. Proteome analysis of brain tissue.** (A–C) Volcano plots of APP23 mice versus WT mice within each diet. Such as seen in liver proteome profiles, some mitochondria-related genes were differentially regulated in brain proteome profiles of APP23 mice (MCEE, ADCK1). However, the majority of differentially regulated proteins is involved in signal transduction, vesicle trafficking, synaptic

function and neuronal plasticity (Syt17, DIP2a, BLOC1s1, SNCB, BAIAP3, WDR11, KCNIP3, TRAPPC13). **(D–F)** Simulated neuronal glucose tolerance of APP23 mice versus WT mice within each diet. Simulated neuronal glucose tolerance did not differ between genotypes and dietary groups. **(G–I)** Simulated neuronal oxygen consumption of APP23 mice versus WT mice within each diet. **(J–L)** Simulated neuronal ATP production of APP23 mice versus WT mice within each diet. Simulated neuronal oxygen consumption and ATP production were slightly elevated in NCD-fed APP23 mice, which might be an overcompensation of beginning mitochondrial dysfunction, resulting in yet unaltered glucose tolerance. Thus, similar analyses in aged APP23 mice with advanced AD pathology would be of interest. Differences in HSD- and HFD-fed APP23 mice were too small to be interpreted. **(A, D, G, J)** NCD; **(B, E, H, K)** HSD; **(C, F, I, L)** HFD. Abbreviations: WT: wild type control; APP23: transgenic mouse model; NCD: normal-control diet; HSD: high-sucrose diet; HFD: high-fat diet.

## Supplementary Tables

**Supplementary Table 1. Detailed ingredients of NCD, HSD, and HFD.**

	<b>NCD</b>	<b>HSD</b>	<b>HFD</b>
Product No.	D16022602	D16022604	D12492
<b>Ingredient (g)</b>			
Casein	160.5	160.5	200
DL-Methionine	3.0	3.0	0
L-Cystine	0	0	3.0
Corn starch	442.5	0	0
Maltodextrin 10	125.0	25.0	125.0
Sucrose	0	542.5	68.8
Cellulose, BW200	50.0	50.0	50.0
Corn oil	98.4	98.4	0
Soybean oil	0	0	25.0
Lard	0	0	245.0
t-Butylhydroquinone	0.02	0.02	0
Mineral mix S10022M	35.0	35.0	0
Mineral mix S10026	0	0	10.0
Vitamin mix V10037	10.0	10.0	0
Vitamin mix V10001	0	0	10.0
Choline bitartate	2.5	2.5	2.0
Dicalcium phosphate	0	0	13.0
Calcium carbonate	0	0	5.5
Potassium citrate	0	0	16.5

Abbreviations: NCD: normal-control diet; HSD: high-sucrose diet; HFD: high-fat diet.

**Supplementary Table 2. Corresponding p-values to significant comparisons shown in Figure 5.**

<b>Parameter</b>	<b>Time-point</b>	<b>Comparison (A vs. B)</b>	<b>Difference (B in relation to A)</b>	<b>P</b>
AUC	Week 12	NCD WT vs. HFD WT	+ 83%	<0.001
		NCD APP23 vs. HFD APP23	+ 56%	<0.001
		HSD WT vs. HFD WT	+ 59%	<0.001
		HSD APP23 vs. HFD APP23	+ 76%	0.009
		HFD WT vs. HFD APP23	- 20%	0.017
	Week 20	NCD WT vs. HFD WT	+ 104%	<0.001
		NCD APP23 vs. HFD APP23	+ 85%	<0.001
		HSD WT vs. HFD WT	+ 63%	<0.001
		HSD APP23 vs. HFD APP23	+ 51%	<0.001
		HFD WT vs. HFD APP23	- 15%	0.049
Fasting glucose	Week 12	NCD APP23 vs. HSD APP23	+ 25%	<0.001
		NCD WT vs. HFD WT	+ 26%	0.004
		NCD APP23 vs. HFD APP23	+ 30%	0.011
		HSD WT vs. HFD WT	+ 21%	0.014
	Week 20	NCD APP23 vs. HSD APP23	+ 18%	0.027
		NCD WT vs. HFD WT	+ 21%	0.002
		HSD WT vs. HFD WT	+ 19%	0.004
		NCD APP23 vs. HFD APP23	+ 35%	0.003
Fasting insulin	Week 12	NCD WT vs. HFD WT	+ 231%	0.001
		NCD APP23 vs. HFD APP23	+ 305%	0.009
		HSD WT vs. HFD WT	+ 231%	0.003
		HSD APP23 vs. HFD APP23	+ 174%	0.039
	Week 20	NCD WT vs. HFD WT	+ 522%	<0.001
		NCD APP23 vs. HFD APP23	+ 267%	<0.001
		HSD WT vs. HFD WT	+ 479%	<0.001
		HSD APP23 vs. HFD APP23	+ 288%	<0.001

Statistical tests are described in the respective figure legend. Differences are displayed as percentage in relation to the first group of the comparison (e.g. NCD WT vs HFD WT +83% means that HFD WT shows 83% more than NCD WT). Abbreviations: AUC: area under the curve.

**Supplementary Table 3. Corresponding p-values to significant comparisons shown in Figure 6.**

<b>Parameter</b>	<b>Time-point</b>	<b>Comparison (A vs. B)</b>	<b>Difference (B in relation to A)</b>	<b>P</b>
O <sub>2</sub> consumption	Baseline	WT vs. APP23	+ 12%	<0.001
		NCD WT vs. NCD APP23	+ 22%	0.030
	Week 12	HSD WT vs. HSD APP23	+ 15%	0.013
		HFD WT vs. HFD APP23	+ 16%	0.002
	Week 20	NCD WT vs. NCD APP23	+ 22%	0.013
		HSD WT vs. HSD APP23	+ 14%	0.057
		HFD WT vs. HFD APP23	+ 10%	<0.001
CO <sub>2</sub> production	Baseline	WT vs. APP23	+ 11%	<0.001
		NCD WT vs. NCD APP23	+ 14%	<0.001
		HFD WT vs. HFD APP23	+ 14%	0.003
	Week 12	NCD WT vs. HFD WT	- 10%	0.051
		NCD APP23 vs. HFD APP23	- 10%	0.003
		HSD WT vs. HFD WT	- 15%	<0.001
		HSD APP23 vs. HFD APP23	- 9%	<0.001
	Week 20	NCD WT vs. NCD APP23	+ 16%	0.018
		HFD WT vs. HFD APP23	+ 13%	<0.001
		NCD WT vs. HFD WT	- 18%	<0.001
		NCD APP23 vs. HFD APP23	- 20%	<0.001
		HSD WT vs. HFD WT	- 22%	<0.001
		HSD APP23 vs. HFD APP23	- 15%	<0.001
	Respiratory exchange ratio	Week 12	HSD WT vs. HSD APP23	- 9%
NCD WT vs. HFD WT			- 16%	<0.001
NCD APP23 vs. HFD APP23			- 11%	0.009
HSD WT vs. HFD WT			- 16%	<0.001
HSD APP23 vs. HFD APP23			- 9%	0.003
Week 20		HSD WT vs. HSD APP23	- 10%	0.020
		NCD WT vs. HSD WT	+ 7%	0.049
		NCD WT vs. HFD WT	- 16%	<0.001
		NCD APP23 vs. HFD APP23	- 14%	<0.001
		HSD WT vs. HFD WT	- 22%	<0.001
		HSD APP23 vs. HFD APP23	- 14%	<0.001
Activity	Baseline	WT vs. APP23	+ 38%	0.009
		NCD WT vs. NCD APP23	+ 84%	0.016
	Week 12	HFD WT vs. HFD APP23	+ 57%	0.061
		NCD APP23 vs. HFD APP23	- 46%	0.016
	Week 20	HSD WT vs. HFD WT	- 46%	0.004
		NCD WT vs. NCD APP23	+ 50%	0.010
		HFD WT vs. HFD APP23	+ 71%	0.007
		NCD APP23 vs. HFD APP23	- 44%	0.001
		NCD WT vs. HFD WT	- 50%	<0.001
		HSD WT vs. HFD WT	- 60%	0.007
		HSD APP23 vs. HFD APP23	- 40%	0.002

Statistical tests are described in the respective Figure legend. Differences are displayed as percentage in relation to the first group of the comparison (e.g. NCD WT vs HFD WT +83% means that HFD WT shows 83% more than NCD WT).



**Supplementary Table 4. Results of spearman correlation of energy expenditure with lean mass, corresponding to Figure 6J–6L and Supplementary Figure 1J–1L, and to Supplementary Figure 2G–2I, 2P–2R.**

<b>Figure</b>	<b>Time-point</b>	<b>r<sub>WT</sub></b>	<b>p<sub>WT</sub></b>	<b>r<sub>APP23</sub></b>	<b>p<sub>APP23</sub></b>
Figure 6J-L	Baseline	0.348	0.041	0.607	0.001
	Week 12	0.662	<0.001	0.673	<0.001
	Week 20	0.615	<0.001	0.550	0.003
Supplementary Figure 1J–1L	Baseline	0.511	0.002	0.696	<0.001
	Week 12	0.662	<0.001	0.769	<0.001
	Week 20	0.734	<0.001	0.816	<0.001
Supplementary Figure 2G–2I	Baseline	0.179	0.305	0.642	<0.001
	Week 12	0.503	0.002	0.653	<0.001
	Week 20	0.488	0.003	0.489	0,004
Supplementary Figure 2P–2R	Baseline	0.417	0.013	0.629	<0.001
	Week 12	0.624	<0.001	0.793	<0.001
	Week 20	0.638	<0.001	0.826	<0.001